Document Detail

Intracystic bleomycin therapy for craniopharyngioma in children: the Canadian experience.
MedLine Citation:
PMID:  17407137     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Surgical removal and radiation therapy are associated with significant risk for morbidity in the pediatric population with craniopharyngioma. Intracystic therapies have been utilized in some centers to potentially decrease morbidity associated with cystic craniopharyngioma. The aim of the study was to review the Canadian experience with intracystic bleomycin therapy (ICB). METHODS: All centers in the Canadian Pediatric Brain Tumor Consortium (CPBTC) were invited to participate in a retrospective review of this treatment. A questionnaire was sent to each center. The data were analyzed at British Columbia's Children's Hospital. RESULTS: In all, 6 of 17 centers utilized ICB and submitted data. A total of 17 of 19 patients with the intention to treat received bleomycin. Twelve were treated at the time of diagnosis, and 5 at the time of recurrence. Five patients achieved a complete response, 6 achieved a partial response, and 5 achieved a minor response to bleomycin. One patient was stable for 2.8 years. At the time of last follow-up, 8 patients have not required further intervention. Complications included transient symptomatic peritumoral edema (2 patients), precocious puberty (1 patient) and panhypopituitarism (2 patients). The median follow-up was 4 years (range, 0.5-10.2 years). The median progression-free survival was 1.8 years (range, 0.3-6.1 years). One patient died of a massive infarct secondary to radiation-induced moyamoya syndrome. CONCLUSIONS: ICB was found to be well tolerated in this group of children. ICB may be a feasible and effective therapy for certain children with craniopharyngioma. Bleomycin may delay the need for aggressive surgery or radiation therapy for several years. Prospective multiinstitutional clinical trials are required to further evaluate the feasibility, effectiveness, and dose schedules of this treatment.
Juliette Hukin; Paul Steinbok; Lucie Lafay-Cousin; Glenda Hendson; Douglas Strother; Claude Mercier; Yvan Samson; William Howes; Eric Bouffet
Related Documents :
21782087 - Pharmacologic pupil dilation as a predictive test for the risk for intraoperative flopp...
9452237 - Arteriovenous malformations in the basal ganglia and thalamus: management and results i...
15662807 - Gamma knife surgery for trigeminal neuralgia: improved initial response with two isocen...
7869017 - Radiation treatment of retinoblastoma: experience in the past two decades.
11316027 - Effectiveness of laser in situ keratomileusis with the nidek ec-5000 excimer laser for ...
12209437 - Thermal chondroplasty with bipolar and monopolar radiofrequency energy: effect of treat...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  Cancer     Volume:  109     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2007 May 
Date Detail:
Created Date:  2007-05-03     Completed Date:  2007-06-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2124-31     Citation Subset:  AIM; IM    
Copyright Information:
(c) 2007 American Cancer Society
Division of Neurology and Oncology, British Columbia's Children's Hospital, Vancouver, British Columbia, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / administration & dosage*,  adverse effects
Bleomycin / administration & dosage*,  adverse effects
Child, Preschool
Craniopharyngioma / drug therapy*,  radiography
Disease-Free Survival
Injections, Intralesional
Pituitary Neoplasms / drug therapy*,  radiography
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 11056-06-7/Bleomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Most human Alu and murine B1 repeats are unique.
Next Document:  Risk factors for malignancy in Japanese renal transplant recipients.